‹ ›
MYP_048937
← PREVIOUS NEXT → BACK
Basic Information
P19(derived from E2 envelope protein of GB virus C)
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Standard
18 amino acids
C94H131N23O24S
Standard
Sequence
LPAFCQAIGWGDPITHWS
Physicochemical Analysis
1999.25 Da
5.08
-1.16
-1.43
-0.0645
0.23
0.32
0.39
26.15
76.11
0.1667
11000.00
11000.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
721.55
-4.21
25.0
25.0
55.0
142.0
8.0
18.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0256025 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
inhibition of HIV
71.4 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperEffect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. | Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. | J Med Chem. 2010 Aug 26;53(16):6054-63. | DOI:10.1021/jm100452c | PMID:20718496 PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0296899 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1
194.3 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperEffect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. | Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. | J Med Chem. 2010 Aug 26;53(16):6054-63. | DOI:10.1021/jm100452c | PMID:20718496 PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0322100 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
inhibition of HIV(HXB2) infection in TZM-bl Cells
46 μM
IC50
PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0410370 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells
369.5 μM
IC50
PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0425064 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Defensin
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1
PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
FIRST PREV 1 2
Showing 5 records on this page · Page 2 of 2